Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone609-275-0500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.52 billion
Profitability
Miscellaneous
Employees4,500
Next Earnings Date4/22/2020 (Estimated)
OptionableOptionable
Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions
What is Integra Lifesciences' stock symbol?
Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."
When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?
Shares of Integra Lifesciences split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly created shares were distributed to shareholders after the market closes on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.
How were Integra Lifesciences' earnings last quarter?
Integra Lifesciences Holdings Corp (NASDAQ:IART) announced its earnings results on Wednesday, February, 19th. The life sciences company reported $0.68 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.67 by $0.01. The life sciences company had revenue of $395.13 million for the quarter, compared to analyst estimates of $397.51 million. Integra Lifesciences had a net margin of 3.31% and a return on equity of 16.94%. The firm's revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.65 earnings per share. View Integra Lifesciences' Earnings History.
When is Integra Lifesciences' next earnings date?
What guidance has Integra Lifesciences issued on next quarter's earnings?
Integra Lifesciences updated its FY20 earnings guidance on Wednesday, February, 19th. The company provided earnings per share (EPS) guidance of $3.00-3.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.00. The company issued revenue guidance of $1.55-1.57 billion, compared to the consensus revenue estimate of $1.59 billion.
What price target have analysts set for IART?
10 Wall Street analysts have issued twelve-month price targets for Integra Lifesciences' stock. Their forecasts range from $56.00 to $75.00. On average, they expect Integra Lifesciences' stock price to reach $63.10 in the next year. This suggests a possible upside of 6.5% from the stock's current price. View Analyst Price Targets for Integra Lifesciences.
What is the consensus analysts' recommendation for Integra Lifesciences?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Integra Lifesciences.
Has Integra Lifesciences been receiving favorable news coverage?
Media stories about IART stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Integra Lifesciences earned a daily sentiment score of 0.7 on InfoTrie's scale. They also gave press coverage about the life sciences company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Integra Lifesciences.
Are investors shorting Integra Lifesciences?
Integra Lifesciences saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,380,000 shares, an increase of 7.8% from the January 15th total of 1,280,000 shares. Based on an average daily volume of 411,200 shares, the short-interest ratio is presently 3.4 days. Currently, 1.9% of the company's stock are short sold. View Integra Lifesciences' Current Options Chain.
Who are some of Integra Lifesciences' key competitors?
Some companies that are related to Integra Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD).
What other stocks do shareholders of Integra Lifesciences own?
Who are Integra Lifesciences' key executives?
Integra Lifesciences' management team includes the folowing people:
- Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
- Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
- Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
- Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
- Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)
Who are Integra Lifesciences' major shareholders?
Integra Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (10.62%), Champlain Investment Partners LLC (7.07%), Janus Henderson Group PLC (5.02%), State Street Corp (2.11%), Capital International Investors (1.45%) and ArrowMark Colorado Holdings LLC (1.39%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, John Mooradian, Joseph Vinhais, Keith Bradley, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy, Rhonda Germany Ballintyn, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.
Which institutional investors are selling Integra Lifesciences stock?
IART stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Capital Bank & Trust Co, Renaissance Technologies LLC, Castleark Management LLC, Capital International Inc. CA, Fort Washington Investment Advisors Inc. OH, Sei Investments Co. and Capital International Investors. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Eric Schwartz, Glenn Coleman, John Mooradian, Kenneth Burhop, Lisa Evoli, Peter J Arduini, Raymond G Murphy and Richard E Caruso. View Insider Buying and Selling for Integra Lifesciences.
Which institutional investors are buying Integra Lifesciences stock?
IART stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Goldman Sachs Group Inc., Champlain Investment Partners LLC, Eaton Vance Management, ArrowMark Colorado Holdings LLC, Mesirow Financial Investment Management Equity Management, Prudential Financial Inc. and GW&K Investment Management LLC. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Rhonda Germany Ballintyn. View Insider Buying and Selling for Integra Lifesciences.
How do I buy shares of Integra Lifesciences?
Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Integra Lifesciences' stock price today?
One share of IART stock can currently be purchased for approximately $59.27.
How big of a company is Integra Lifesciences?
Integra Lifesciences has a market capitalization of $5.09 billion and generates $1.52 billion in revenue each year. The life sciences company earns $60.80 million in net income (profit) each year or $2.74 on an earnings per share basis. Integra Lifesciences employs 4,500 workers across the globe.View Additional Information About Integra Lifesciences.
What is Integra Lifesciences' official website?
How can I contact Integra Lifesciences?
Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]
MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
